Immuneering (Nasdaq:IMRX) - 주가, 뉴스 및 분석

IMRX 주식 개요

임상 단계의 종양학 회사인 이뮤네링은 광범위한 암 환자를 위한 의약품을 개발하는 회사입니다. 자세한 내용

IMRX 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	4/6
배당금	0/6

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

수익은 향후 3년간 연평균 11.3% 씩 감소할 것으로 예상됩니다.

cash runway 경력이 1년 미만입니다.

최근 3개월간 주가 변동폭 심해

+ 3 더 많은 위험

Immuneering Corporation 경쟁사

SELLAS Life Sciences Group

NasdaqCM:SLS

US$82.3m

Leap Therapeutics

NasdaqCM:LPTX

US$111.9m

I-Mab

NasdaqGM:IMAB

US$77.5m

Entera Bio

NasdaqCM:ENTX

US$62.6m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Immuneering
과거 주가
현재 주가	US$2.13
52주 최고치	US$8.89
52주 최저치	US$1.00
베타	-0.40
11개월 변경	10.94%
3개월 변경 사항	91.89%
1년 변경 사항	-74.24%
33년 변화	-89.00%
5년 변화	n/a
IPO 이후 변화	-87.89%

최근 뉴스 및 업데이트

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Aug 30

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

May 13

Recent updates

주주 수익률

	IMRX	US Biotechs	US 마켓
7D	1.4%	2.4%	0.5%
1Y	-74.2%	15.6%	30.7%

수익률 대 산업: IMRX 지난 1년 동안 15.6 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: IMRX 지난 1년 동안 30.7 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is IMRX's price volatile compared to industry and market?
IMRX volatility
IMRX Average Weekly Movement	23.2%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

안정적인 주가: IMRX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: IMRX 의 주간 변동성( 23% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2008	66	Ben Zeskind	immuneering.com

임상 단계의 종양학 회사인 이뮤네링은 광범위한 암 환자를 위한 의약품을 개발하고 있습니다. 주요 제품 후보로는 췌장암, 흑색종, 대장암, 비소세포폐암 등 RAS 및/또는 RAF 돌연변이로 인한 암 환자 치료를 위해 현재 1/2a상 임상시험 중인 이중 MEK 억제제인 IMM-1-104와 고형암 치료를 위한 연구용 신약 신청 중인 IMM-6-415가 있습니다. 이뮤네링은 2008년에 설립되었으며 매사추세츠주 케임브리지에 본사를 두고 있습니다.

Immuneering Corporation 기본 사항 요약

Immuneering 의 수익과 매출은 시가총액과 어떻게 비교하나요?
IMRX 기본 통계
시가총액	US$66.14m
수익(TTM)	-US$58.07m
수익(TTM)	n/a

0.0x

P/S 비율

-1.1x

P/E 비율

IMRX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
IMRX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$58.07m
수익	-US$58.07m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.87
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	0%

IMRX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

IMRX 주식 개요

위험 분석

Immuneering Corporation 경쟁사

NasdaqCM:SLS

US$82.3m

NasdaqCM:LPTX

US$111.9m

NasdaqGM:IMAB

US$77.5m

NasdaqCM:ENTX

US$62.6m

가격 내역 및 성능

최근 뉴스 및 업데이트

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Recent updates

Immuneering Corporation Announces Positive Initial Phase 2A Data Including Complete and Partial Responses with Imm-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell Small Cap Comp Value Index

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering Corporation, Annual General Meeting, Jun 12, 2024

Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting

Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations

Independent Chair recently bought US$123k worth of stock

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Price target decreased by 12% to US$16.86

Immuneering Announces Positive Topline Results from Phase 1 Portion of Its Phase 1/2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Share price stability

Less than half of directors are independent

Immuneering Corporation Appoints Thomas J. Schall to Its Board of Directors

Immuneering Doses First Patient in Phase 2A Clinical Trial of IMM-1-104 in Ras-Mutant Solid Tumors

New major risk - Revenue and earnings growth

Immuneering Corporation Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

New major risk - Share price stability

Third quarter 2023 earnings released: US$0.43 loss per share (vs US$0.49 loss in 3Q 2022)

New minor risk - Share price stability

Immuneering Corporation Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

First half 2023 earnings released: US$0.93 loss per share (vs US$0.93 loss in 1H 2022)

Immuneering Corporation Appoints Mallory Morales as Chief Accounting Officer, Effective July 1, 2023

New major risk - Revenue and earnings growth

First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.49 loss in 1Q 2022)

Price target decreased by 12% to US$18.71

Consensus revenue estimates decrease by 80%, EPS upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$21.33

Immuneering Corporation Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations

Consensus revenue estimates fall by 26%

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Immuneering Corporation Appoints Leah R. Neufeld as Chief People Officer

Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering wins FDA nod to study lead asset in solid tumors

Immuneering Corporation Announces Committee Changes

Consensus forecasts updated

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2A Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Immuneering Corporation Announces Management Changes

Immuneering initiated a Buy by Chardan, PT set to $18

Immuneering Corporation(NasdaqGM:IMRX) dropped from Russell 2500 Value Index

Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104

Consensus forecasts updated

First quarter 2022 earnings: EPS misses analyst expectations

Immuneering Corporation, Annual General Meeting, Jun 21, 2022

Consensus revenue estimates fall by 75%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Immuneering Corporation Reports Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model

Immuneering Corporation (NasdaqGM:IMRX) acquired BioArkive, Inc. from Brett Hall, Praveen Nair, Daniel Flynn, Thomas Barr, Anna Travesa and Dennis Garland for $8.5 million.

Third quarter 2021 earnings released: US$0.47 loss per share

Director recently bought US$116k worth of stock

Director recently bought US$131k worth of stock

Less than half of directors are independent

주주 수익률